Related Experiment Video
Updated: Aug 3, 2026
07:20
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 15, 2011
Maintenance therapy with interferon alfa 2b in patients with diffuse large cell lymphoma
A Avilés1, J C Díaz-Maqueo, E L García
1Department of Hematology, Oncology Hospital, National Medical Center, IMSS, México, D.F.
Investigational New Drugs
|November 1, 1992
Summary
Interferon alfa 2b (IFN) maintenance therapy significantly improved remission duration and survival in diffuse large cell lymphoma (DLCL) patients. This therapy offers a beneficial option for DLCL patients in complete remission after chemotherapy.
Area of Science:
- Oncology
- Hematology
- Clinical Trials
Background:
- Diffuse large cell lymphoma (DLCL) is a significant hematologic malignancy.
- Complete remission (CR) after conventional chemotherapy is a critical treatment goal.
- Maintenance therapy strategies for DLCL in CR require further investigation.
Purpose of the Study:
- To evaluate the efficacy of interferon alfa 2b (IFN) as maintenance therapy in DLCL patients.
- To compare the duration of complete remission (CR) and survival rates between IFN-treated and control groups.
- To assess the toxicity profile of IFN maintenance therapy in DLCL.
Main Methods:
- Prospective clinical trial involving 48 DLCL patients in CR post-chemotherapy.
- Random assignment to either no maintenance or interferon alfa 2b (IFN) 5.0 MU thrice weekly for one year.
- Kaplan-Meier analysis for progression-free survival and overall survival.
Main Results:
- The median duration of CR in the IFN group was not reached, versus 40 months in the control group (p < 0.001).
- Five-year CR rates were 60% with IFN versus an unspecified rate in controls.
- Actuarial five-year survival was 88% for IFN-treated patients compared to 42% for controls (p < 0.001).
Conclusions:
- Interferon alfa 2b (IFN) maintenance therapy demonstrates significant benefit in prolonging CR and improving survival for DLCL patients.
- IFN therapy offers an effective alternative with potentially lower toxicity compared to some conventional chemotherapy regimens.
- Further controlled clinical trials are warranted to explore IFN's role in DLCL management.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...